

Saturday, November 2, 2024 8:15 a.m.–4:00 p.m. Virtual Program

Massachusetts Psychiatric Society's 35th Annual Psychopharmacology Update

Program Overview

Each year the psychopharmacology update course chair and cochair review feedback from the previous year including suggestions for topics of interest. Also, the organizers have extensive experience consulting with psychiatrists who have psychopharmacology questions and become aware of prescribing issues that are not well understood by practitioners. From these sources, a set of presentations was developed. The program begins with a discussion on the differential diagnosis and treatment of bipolar depression. A second speaker will focus on truths and fallacies of psychopharmacology. This will be followed by a speaker providing evidence-based approaches on how to

deprescribe in older adults. The program continues with a discussion on the treatment of generalized anxiety in older adults. After a lunch break, there is a discussion on what happens when we dose medications beyond their regulatory limits. The final lecture will be on the topic of advances in the treatment of major depressive disorder with psychotic features. The program will end with questions and answers on any topic in psychopharmacology with a panel of the day's speakers.

Learning Objectives

At the conclusion of this activity, participants should be able to:

- Prescribe medications without being subject to undue influence by drug company marketing
- Select the most evidence-supported medications for efficacy and safety for patients with bipolar depression
- Select the most evidence-supported medications for efficacy and safety for patients with psychiatric disorders, especially appreciating important truths and fallacies of psychopharmacology
- Appreciate the evidence-based way of deprescribing in older adults.
- Select the most evidence-supported medications for efficacy and safety for patients with generalized anxiety in older adults
- Select the most evidence-supported medications for efficacy and safety for patients who might require medication doses beyond regulatory limits
- Select the most evidence-supported medications for efficacy and safety for patients with major depressive disorder with psychotic features.

CLICK TO REGISTER ONLINE

AMA Credit Designation Statement

The Massachusetts Psychiatric Society designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement

The Massachusetts Psychiatric Society is accredited by the Massachusetts Medical Society to provide continuing medical education for physicians.

REGISTRATION FEE

MPS/APA/MMS MEMBER	\$150
RESIDENT/FELLOW	\$15
NON-MEMBER	\$175
MEDICAL STUDENT	\$0

Questions?

Call (781) 237-8100, 8 a.m.–4 p.m. Monday thru Friday



Faculty



Christopher Aiken, MD Editor-in-Chief, Carlat Psychiatry Report Assistant Professor of Psychiatry, New York University and Wake Forest Schools of Medicine



Nassir Ghaemi, MD, MPH, DLFAPA

President, Massachusetts Psychiatric Society

Lecturer on Psychiatry, Harvard Medical School



Anderson Chen, MD Psychiatrist, Massachusetts General Hospital Instructor in Psychiatry, Harvard Medical School



David N. Osser, MD Associate Professor of Psychiatry, Harvard Medical School at VA Boston Healthcare System



Stephanie Collier, MD, MPH Director of Education, Division of Geriatric Psychiatry at McLean Hospital



Anthony J. Rothschild, MD

Irving S. and Betty Brudnick Endowed Chair and Professor of Psychiatry Vice-Chair for Research, Department of Psychiatry University of Massachusetts Chan Medical School

Editor-in Chief, Journal of Clinical Psychopharmacology



Program Schedule

8:15-8:30 a.m.	Welcome and Introduction Anderson Chen, MD, Activity Chair David N. Osser, MD, Activity Co-Chair
8:30-9:30 a.m.	Bipolar Depression Algorithm Update <i>David N. Osser, MD</i>
9:30-10:30 a.m.	Truths and Fallacies of Psychopharmacology Nassir Ghaemi, MD, MPH, DLFAPA
10:30-10:45 a.m.	BREAK
10:45-11:45 p.m.	Deprescribing in Older Adults Stephanie Collier, MD
11:45-12:45 p.m.	A potential algorithm for the treatment of GAD in older adults <i>Anderson Chen, MD</i>
12:45-1:30 p.m.	LUNCH
1:30-2:30 p.m.	High Dose Psychiatry Christopher Aiken, MD
2:30-3:30 p.m.	Advances in the treatment of Major Depressive Disorder with psychotic features <i>Anthony J. Rothschild, MD</i>
3:30-4:00 p.m.	More Questions and Answers Panel of the Speakers